Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Ribociclib delays QoL deterioration and pain progression in HR+/HER2- advanced breast cancer

Addition of targeted therapy extends time to definitive deterioration across functional and pain scales compared to placebo, contradicting typical toxicity trade-offs

Design · Phase III Randomized Clinical Trial (MONALEESA-3) N · 726 Population · Patients with HR+/HER2- advanced breast cancer Duration · Median follow-up 20.4 months Arms · Ribociclib + Fulvestrant vs. Placebo + Fulvestrant Randomized (2:1) Double-blind QoL assessment via EORTC QLQ-C30 & BPI-SF

Key Performance Indicators

PRIMARY
Pain Severity TTD HR
0.77
95% CI: 0.57–1.05
23% risk reduction in pain worsening
Emotional Functioning TTD HR
0.76
95% CI: 0.57–1.01
24% risk reduction in emotional decline
Global Health TTD HR
0.81
95% CI: 0.62–1.1
19% risk reduction in global health decline
Baseline Global Score
65.5
vs 68.4 (Placebo)
Balanced baseline QoL
1

Consistent Hazard Ratio Benefit Across All QoL Domains

Forest plot displaying Hazard Ratios for Time to Deterioration (TTD). While Confidence Intervals cross 1.0, the consistent leftward shift (HR < 0.82) across Global, Physical, Emotional, and Pain metrics indicates a systemic benefit in delaying deterioration with Ribociclib.

2

Extension of Symptom-Free Survival (Months)

Slope chart visualizing the absolute time gain in TTD. Ribociclib (G1) consistently extends the median/mean time to deterioration compared to Placebo (G2), with the most dramatic preservation seen in Emotional Functioning (+8.2 months) and Pain Severity (+6.8 months).

3

Holistic Preservation of Patient Function

Radar chart mapping the months to deterioration across four key axes (Global, Physical, Emotional, Pain). The Ribociclib polygon fully encapsulates the Placebo polygon, demonstrating that the addition of the drug expands the 'envelope' of preserved quality of life.

4

Pain Management Advantage: +6.8 Months

Lollipop chart focusing specifically on the BPI-SF Pain Severity Index. It highlights the tangible clinical benefit: patients on Ribociclib maintain lower pain levels for nearly 7 months longer (42.7 months) than those on Placebo (35.9 months).

Editorial Conclusion

"Ribociclib plus fulvestrant demonstrates a consistent trend in delaying the deterioration of health-related quality of life and pain scores compared to placebo."
Pain severity deterioration delayed by nearly 7 months (HR 0.77).
Emotional functioning preserved for over 8 months longer than placebo.
No detriment to Global Health Status despite addition of active treatment.
Clinical Implication
These PRO results support the overall clinical benefit of ribociclib, suggesting efficacy gains do not come at the cost of accelerated quality of life decline.

Reference Data & Sources

Complete Data Table

Abbreviations

HR = Hazard Ratio · CI = Confidence Interval · TTD = Time to Definitive Deterioration · QoL = Quality of Life · PRO = Patient-Reported Outcomes

Source

The Breast 54 (2020) 148-154
DOI: 10.1016/j.breast.2020.09.008

Limitations

Differences were not statistically significant (CIs crossed 1) No post-progression PRO assessments performed

Provenance Index

Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode